Using large-scale brain modelling and dynamic sensitivity analysis of resting-state data in responders versus non-responders, the study identified specific brain regions whose perturbation predicts a transition from depressive to healthy brain dynamics following psilocybin therapy. These regions co-localise with in vivo 5-HT2A and 5-HT1A receptor density maps, providing causal mechanistic evidence that serotonergic targets mediate psilocybin's therapeutic effect in treatment-resistant depression.
- Published
- Journal
- Brain Communications
- Authors
- Vohryzek, J., Cabral, J., Lord, L. D., Fernandes, H. M., Roseman, L., Nutt, D. J., Carhart-Harris, R. L., Deco, G., Kringelbach, M. L.